Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "Fid"

883 News Found

RxDx Healthcare receives NABL accreditation
Clinical Trials | September 20, 2021

RxDx Healthcare receives NABL accreditation

RxDx is a chain of primary care driven multispecialty healthcare clinics with two main branches situated in Whitefield and Malleswaram in Bengaluru


Imfinzi plus chemotherapy tripled patient survival at 3 years
Biotech | September 20, 2021

Imfinzi plus chemotherapy tripled patient survival at 3 years

The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting


Samhita and Cipla collaborate to study the role of pharmacists in healthcare
Public Health | September 18, 2021

Samhita and Cipla collaborate to study the role of pharmacists in healthcare

Over 61 per cent of pharmacists stated that they aim to improve their knowledge and medical skills while 76 per cent collaborated with healthcare players to improve the outcome for their patients


Promising prospects for Indian pharma: CLSA
News | September 17, 2021

Promising prospects for Indian pharma: CLSA

CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report


NCLT approves amalgamation of Lincoln Parenteral with Lincoln Pharma
News | September 16, 2021

NCLT approves amalgamation of Lincoln Parenteral with Lincoln Pharma

The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity


Biocon settles suit with Celgene for generic Revlimid
Biotech | September 08, 2021

Biocon settles suit with Celgene for generic Revlimid

Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020


Japan to purchase 150 million doses of Novavax’ Covid-19 vaccine from Takeda
Biotech | September 08, 2021

Japan to purchase 150 million doses of Novavax’ Covid-19 vaccine from Takeda

Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022


HUL funds study on Covid-19 vulnerability and vaccine efficiency
News | September 07, 2021

HUL funds study on Covid-19 vulnerability and vaccine efficiency

The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.


Max Ventilator forms partnership with US-based Amptron Medical
Drug Approval | September 07, 2021

Max Ventilator forms partnership with US-based Amptron Medical

Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.